Due to database restrictions and the need for consistency among databases and departments, the Emory Office for Clinical Research (OCR) has developed guidance in creating the Short Study Title. The Databases used to determine this guidance: OnCore, EPIC, Vestigo, ClinicalTrials.gov, Salesforce Study log, and eIRB submission.
- The Short Study Title should be based upon the information in the protocol document. If the Short Study Title is given in the protocol document, please use this as the short title.
- It should not be any longer than 50 characters, due to database character limitations
- Avoid the use of any special characters (e.g., &,#,@, commas, etc.) Stay with letters, numbers, period, parentheses, and the use of (-) dash. Please be cautious of the use of blank spaces in front of (preceding) the title and at the end of titles; these spaces and characters can be problematic with some databases and interfaces.
Good Examples of Short Study Title:
- Most protocols have a Short Study Title, use an acronym or theme word and these can be used
- Examples: DFHCC-16593, Winship4441-18, I-SPY2, PUSH, TRANSFORM
Examples of Short Study Titles to Avoid:
- Avoid using drug name or Sponsor name, as these can be the same across multiple protocols
- Examples: Genetech-25, Abatacept (TN18), Clarithromycin Mechanisms
- Avoid using the IRB name in the Short Study Title
- Examples: XIRB-345, WIRB789
- **EXCEPTION – Per Emory IRB guidance, when submitting through the eIRB system, it is requested to have the IRB type preceding the Study Short Title. The IRB type should not be part of the Study Short title nomenclature used outside of the eIRB system. Please refer to Emory IRB website for further details regarding the IRB prefix.
- Do Not add extensions:
- Examples: TA799-101 (Complion), KAR-012 (WIRB)